secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001818382-24-000197
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline
-------------------------------------------------------------------------

- Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.
- Cash $71M at Sep 30; received $29.6M net from Oct registered direct offering.
- FDA BLA for ATEV in vascular trauma still under review; no new PDUFA date provided.
- V007 Phase 3 AV access data presented at ASN Kidney Week: ATEV superior patency vs fistula in key subgroups.
- Submitted NTAP reimbursement application to CMS for FY2026 cycle (Oct 2025 effective date if approved).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000197/0001818382-24-000197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000197/huma-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer